Michele Bombardieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4252799/publications.pdf

Version: 2024-02-01

90 papers 5,670 citations

36 h-index 71 g-index

92 all docs 92 docs citations 92 times ranked 6592 citing authors

#	Article	IF	CITATIONS
1	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
2	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.5	27
3	Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology, 2022, 61, 4797-4808.	0.9	20
4	Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. Communications Biology, 2022, 5, 413.	2.0	8
5	Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression. Cell Reports, 2022, 39, 110766.	2.9	20
6	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	15.2	105
7	Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology, 2021, 60, 2396-2408.	0.9	6
8	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	2.5	38
9	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
10	Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000445.	1.1	11
11	PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. PLoS Biology, 2021, 19, e3001199.	2.6	32
12	Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1543-1565.	2.3	37
13	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatology, The, 2021, 3, e553-e562.	2.2	31
14	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in Immunology, 2021, 12, 706737.	2.2	8
15	Stepwise changes in the murine salivary gland immune response during virally-induced ectopic lymphoid structure formation. Clinical and Experimental Rheumatology, 2021, , .	0.4	O
16	Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
17	Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 100-106.	0.4	3
18	Severity of COVID-19 infection in primary Sj \tilde{A} ¶gren's syndrome and the emerging evidence of COVID-19-induced xerostomia. Clinical and Experimental Rheumatology, 2021, 39, 215-222.	0.4	5

#	Article	IF	CITATIONS
19	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.4	12
20	Stepwise changes in the murine salivary gland immune response during virally-induced ectopic lymphoid structure formation. Clinical and Experimental Rheumatology, 2021, 39, 39-48.	0.4	1
21	Cellular and molecular diversity in Sjogren's syndrome salivary glands: Towards a better definition of disease subsets. Seminars in Immunology, 2021, 58, 101547.	2.7	6
22	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.4	0
23	Severity of COVID-19 infection in primary Sjögren's syndrome and the emerging evidence of COVID-19-induced xerostomia Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 215-222.	0.4	О
24	CXCL13 as biomarker for histological involvement in Sjögren's syndrome. Rheumatology, 2020, 59, 165-170.	0.9	25
25	Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren's syndrome. Rheumatology, 2020, 59, 2350-2359.	0.9	54
26	O20 $\hat{a} \in f$ Histological and molecular features of the diseased synovium in early untreated PsA in comparison with RA. Rheumatology, 2020, 59, .	0.9	O
27	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. Annals of the Rheumatic Diseases, 2020, 79, 1588-1599.	0.5	83
28	A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNF \hat{l}_{\pm} -Blockade in Rheumatoid Arthritis Patients. Frontiers in Immunology, 2020, $11,845$.	2.2	55
29	H and L Chain Affinity Maturation and/or Fab <i>N</i> -Glycosylation Influence Immunoreactivity toward Neutrophil Extracellular Trap Antigens in Rheumatoid Arthritis Synovial B Cell Clones. Journal of Immunology, 2020, 204, 2374-2379.	0.4	6
30	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj \tilde{A} ¶gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatology, The, 2020, 2, e142-e152.	2.2	68
31	Impaired Interleukinâ€27–Mediated Control of <scp>CD</scp> 4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjögren's Syndrome. Arthritis and Rheumatology, 2020, 72, 1559-1570.	2.9	15
32	One year in review 2020: pathogenesis of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 3-9.	0.4	8
33	The use of digital image analysis in the histological assessment of Sjögren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 180-188.	0.4	5
34	Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 222-227.	0.4	6
35	Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring. Cell Metabolism, 2019, 30, 1055-1074.e8.	7.2	266
36	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Reports, 2019, 28, 2455-2470.e5.	2.9	241

#	Article	IF	CITATIONS
37	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sj¶gren's syndrome. RMD Open, 2019, 5, e000885.	1.8	14
38	Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. Rheumatology, 2019, , .	0.9	56
39	PTPN14 phosphatase and YAP promote $TGF\hat{l}^2$ signalling in rheumatoid synoviocytes. Annals of the Rheumatic Diseases, 2019, 78, 600-609.	0.5	33
40	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2019, 78, 761-772.	0.5	219
41	B cells in the formation of tertiary lymphoid organs in autoimmunity, transplantation and tumorigenesis. Current Opinion in Immunology, 2019, 57, 46-52.	2.4	31
42	AB0179â€THE TRANSCRIPTION FACTORS IKZF1 AND IKZF3 CONTROL B CELL ACTIVATION AND DIFFERENTIATION IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	N	1
43	THU0058â€B CELL SYNOVITIS AND CLINICAL PHENOTYPES IN RHEUMATOID ARTHRITIS AT DIFFERENT DISEASE STAGES. , 2019, , .		2
44	OPO113â€HISTOLOGICAL AND MOLECULAR PORTRAIT OF THE SYNOVIAL TISSUE IN EARLY TREATMENT-NAÃVE PSORIATIC ARTHRITIS IN COMPARISON WITH RHEUMATOID ARTHRITIS., 2019, , .		2
45	NK cell recruitment in salivary glands provides early viral control but is dispensable for tertiary lymphoid structure formation. Journal of Leukocyte Biology, 2019, 105, 589-602.	1.5	5
46	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
47	Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. Annals of the Rheumatic Diseases, 2019, 78, e28-e28.	0.5	3
48	B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt?. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 217-224.	0.4	7
49	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Annals of the Rheumatic Diseases, 2018, 77, 412-416.	0.5	86
50	$244\hat{a} \in f$ The clinical phenotype of inflammatory arthritis correlates with synovial immune cell infiltration: results from the pathobiology of early arthritis cohort. Rheumatology, 2018, 57, .	0.9	0
51	O09 $\hat{a} \in f$ A lymphoid pathotype at baseline, in early inflammatory arthritis, significantly associates with requirement for biologic therapy at 12 months follow up: results from the pathobiology of early arthritis cohort. Rheumatology, 2018, 57, .	0.9	O
52	Autophagy induces protein carbamylation in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Rheumatology, 2018, 57, 2032-2041.	0.9	12
53	Characterization of a Synovial B Cell–Derived Recombinant Monoclonal Antibody Targeting Stromal Calreticulin in the Rheumatoid Joints. Journal of Immunology, 2018, 201, 1373-1381.	0.4	9
54	Generation of Recombinant Monoclonal Antibodies from Single B Cells Isolated from Synovial Tissue of Rheumatoid Arthritis Patients. Methods in Molecular Biology, 2018, 1845, 159-187.	0.4	2

#	Article	IF	CITATIONS
55	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112.	0.4	37
56	A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 145-149.	0.4	2
57	The role of salivary gland histopathology in primary Sj \tilde{A} \P gren's syndrome: promises and pitfalls. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 222-233.	0.4	22
58	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. Rheumatology International, 2017, 37, 623-631.	1.5	16
59	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.5	200
60	Randomized Controlled Trial of Rituximab and Costâ€Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 1440-1450.	2.9	194
61	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjĶgren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.5	132
62	Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nature Reviews Rheumatology, 2017, 13, 141-154.	3.5	146
63	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. Rheumatology, 2017, 56, e24-e48.	0.9	33
64	Lactate at the crossroads of metabolism, inflammation, and autoimmunity. European Journal of Immunology, 2017, 47, 14-21.	1.6	145
65	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. Rheumatology, 2017, 56, 1643-1647.	0.9	6
66	Kidney Expression of Toll Like Receptors in Lupus Nephritis: Quantification and Clinicopathological Correlations. Mediators of Inflammation, 2016, 2016, 1-7.	1.4	32
67	Ectopic Lymphoid Structures: Powerhouse of Autoimmunity. Frontiers in Immunology, 2016, 7, 430.	2.2	121
68	NETosis as Source of Autoantigens in Rheumatoid Arthritis. Frontiers in Immunology, 2016, 7, 485.	2,2	101
69	Ultrasound of the salivary glands is a strong predictor of labial gland biopsy histopathology in patients with sicca symptoms. Journal of Oral Pathology and Medicine, 2016, 45, 450-454.	1.4	42
70	Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Annals of the Rheumatic Diseases, 2016, 75, 1866-1875.	0.5	176
71	Autophagy generates citrullinated peptides in human synoviocytes: a possible trigger for anti-citrullinated peptide antibodies. Rheumatology, 2016, 55, 1374-1385.	0.9	58
72	Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sj¶gren's Syndrome-Like Phenotype in Vivo. Pathogens and Immunity, 2016, 1, 12.	1.4	57

#	Article	IF	CITATIONS
73	Angiogenic gene expression and vascular density are reflected in ultrasonographic features of synovitis in early rheumatoid arthritis: an observational study. Arthritis Research and Therapy, 2015, 17, 58.	1.6	34
74	Use of Ultrasoundâ€Guided Small Joint Biopsy to Evaluate the Histopathologic Response to Rheumatoid Arthritis Therapy: Recommendations for Application to Clinical Trials. Arthritis and Rheumatology, 2015, 67, 2601-2610.	2.9	39
75	Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLoS Biology, 2015, 13, e1002202.	2.6	489
76	IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11024-11029.	3.3	173
77	Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine, 2015, 212, 1793-1802.	4.2	88
78	Implication of Epsteinâ€Barr Virus Infection in Diseaseâ€Specific Autoreactive B Cell Activation in Ectopic Lymphoid Structures of Sjögren's Syndrome. Arthritis and Rheumatology, 2014, 66, 2545-2557.	2.9	122
79	Peripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis. Drug Discovery Today, 2014, 19, 1161-1165.	3.2	10
80	Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology, 2014, 14, 447-462.	10.6	529
81	Accumulation of Self-Reactive NaÃ⁻ve and Memory B Cell Reveals Sequential Defects in B Cell Tolerance Checkpoints in Sjögren's Syndrome. PLoS ONE, 2014, 9, e114575.	1.1	33
82	A6.5â€Synovial Lymphoid Structures Support Epstein-Barr Virus Persistence and Autoreactive Plasma Cell Infection in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A43.3-A44.	0.5	0
83	Activation of Melanocortin Receptor 3 as a new strategy to control experimental and rheumatoid arthritis. FASEB Journal, 2013, 27, 648.8.	0.2	O
84	Inducible Tertiary Lymphoid Structures, Autoimmunity, and Exocrine Dysfunction in a Novel Model of Salivary Gland Inflammation in C57BL/6 Mice. Journal of Immunology, 2012, 189, 3767-3776.	0.4	103
85	Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren's Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis. Current Pharmaceutical Biotechnology, 2012, 13, 1989-1996.	0.9	45
86	Targeted delivery of anti-inflammatory therapy to rheumatoid tissue by fusion proteins containing an IL-4-linked synovial targeting peptide. Nature Precedings, 2011, , .	0.1	0
87	A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Annals of the Rheumatic Diseases, 2011, 70, 1857-1865.	0.5	105
88	CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjolˆgren's Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization. Journal of Immunology, 2008, 180, 5130-5140.	0.4	172
89	Activation-Induced Cytidine Deaminase Expression in Follicular Dendritic Cell Networks and Interfollicular Large B Cells Supports Functionality of Ectopic Lymphoid Neogenesis in Autoimmune Sialoadenitis and MALT Lymphoma in Sjol^gren's Syndrome. Journal of Immunology, 2007, 179, 4929-4938.	0.4	193
90	I 114 â \in f Is the Answer in the Glands?. Rheumatology, 0, , .	0.9	0